JPS5920227A - ヒト血漿から日和見細菌特異免疫グロブリンを抽出する方法 - Google Patents
ヒト血漿から日和見細菌特異免疫グロブリンを抽出する方法Info
- Publication number
- JPS5920227A JPS5920227A JP12958482A JP12958482A JPS5920227A JP S5920227 A JPS5920227 A JP S5920227A JP 12958482 A JP12958482 A JP 12958482A JP 12958482 A JP12958482 A JP 12958482A JP S5920227 A JPS5920227 A JP S5920227A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- specific
- plasma
- microorganism
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 16
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 16
- 241001465754 Metazoa Species 0.000 title claims abstract description 14
- 210000002381 plasma Anatomy 0.000 title abstract 5
- 244000005700 microbiome Species 0.000 claims abstract description 43
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 11
- 229930006000 Sucrose Natural products 0.000 claims abstract description 11
- 239000005720 sucrose Substances 0.000 claims abstract description 11
- 239000000427 antigen Substances 0.000 claims abstract description 9
- 102000036639 antigens Human genes 0.000 claims abstract description 9
- 108091007433 antigens Proteins 0.000 claims abstract description 9
- 239000002244 precipitate Substances 0.000 abstract description 7
- 230000001376 precipitating effect Effects 0.000 abstract description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 239000002504 physiological saline solution Substances 0.000 description 7
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 235000019260 propionic acid Nutrition 0.000 description 6
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000233866 Fungi Species 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 101000588258 Taenia solium Paramyosin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12958482A JPS5920227A (ja) | 1982-07-27 | 1982-07-27 | ヒト血漿から日和見細菌特異免疫グロブリンを抽出する方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12958482A JPS5920227A (ja) | 1982-07-27 | 1982-07-27 | ヒト血漿から日和見細菌特異免疫グロブリンを抽出する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5920227A true JPS5920227A (ja) | 1984-02-01 |
| JPS6332332B2 JPS6332332B2 (enrdf_load_stackoverflow) | 1988-06-29 |
Family
ID=15013064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12958482A Granted JPS5920227A (ja) | 1982-07-27 | 1982-07-27 | ヒト血漿から日和見細菌特異免疫グロブリンを抽出する方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5920227A (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008020485A (ja) * | 2006-07-10 | 2008-01-31 | Sony Corp | 画像投影システム及びこれに用いるスクリーン |
| US7660037B2 (en) | 2006-06-06 | 2010-02-09 | Seiko Epson Corporation | Screen, projector, and image display device |
| US7922333B2 (en) | 2006-04-27 | 2011-04-12 | Seiko Epson Corporation | Projector, screen, projector system, and scintillation removing apparatus for removing scintillation on an image display using a vibration generating unit |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5344620A (en) * | 1976-09-30 | 1978-04-21 | Green Cross Corp:The | Recovering of immobilized vaccine and specific antigen |
-
1982
- 1982-07-27 JP JP12958482A patent/JPS5920227A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5344620A (en) * | 1976-09-30 | 1978-04-21 | Green Cross Corp:The | Recovering of immobilized vaccine and specific antigen |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7922333B2 (en) | 2006-04-27 | 2011-04-12 | Seiko Epson Corporation | Projector, screen, projector system, and scintillation removing apparatus for removing scintillation on an image display using a vibration generating unit |
| US7660037B2 (en) | 2006-06-06 | 2010-02-09 | Seiko Epson Corporation | Screen, projector, and image display device |
| US7986457B2 (en) | 2006-06-06 | 2011-07-26 | Seiko Epson Corporation | Screen, projector, and image display device |
| JP2008020485A (ja) * | 2006-07-10 | 2008-01-31 | Sony Corp | 画像投影システム及びこれに用いるスクリーン |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6332332B2 (enrdf_load_stackoverflow) | 1988-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI89278C (fi) | Metod foer framstaellning av monoklonal human antikropp mot serotypiska lipopolysackariddeterminanter pao gramnegativa bakterier | |
| Ribi et al. | Endotoxic and antigenic fractions from the cell wall of Salmonella enteritidis. Methods for separation and some biologic activities | |
| TW403655B (en) | Novel attenuated pseudomonas aeruginosa strains | |
| SE448062B (sv) | Sett att framstella ett proteinkoncentrat innehallande immunologiska faktorer herrorande fran mjolk | |
| Ashkenazi et al. | Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome | |
| Tu et al. | The role of macrophages in the protection of mice against leptospirosis: in vitro and in vivo studies | |
| Karjalainen et al. | Cloning of a genetic determinant from Clostridium difficile involved in adherence to tissue culture cells and mucus | |
| Nowicki et al. | Fimbrial phase variation and systemic E. coli infection studied in the mouse peritonitis model | |
| FR2593826A1 (fr) | Anticorps monoclonaux a reactivite et a protectivite croisees vis-a-vis des serotypes de p. aeruginosa | |
| AT398781B (de) | Unsterbliche zellinie und deren verwendung | |
| DE69329642T3 (de) | Breitreaktive opsonische antikörper die mit gemeinsamen antigenen von staphylococcus reagieren | |
| Ellner et al. | Aeromonas shigelloides bacteremia: a case report | |
| JPH06505730A (ja) | ヒトにおいてエンテロトキシン産生大腸菌により起こる腸感染症／下痢に対して接種するためのホルマリン殺菌したコロニー形成因子抗原（ｃｆａ）−発現性大腸菌の調製および使用 | |
| JPS5920227A (ja) | ヒト血漿から日和見細菌特異免疫グロブリンを抽出する方法 | |
| JP4002187B2 (ja) | 抗ふけ菌免疫抗体及びその用途 | |
| Anderson et al. | Opsonophagocytosis of Pseudomonas aeruginosa treated with antiflagellar serum | |
| FI74475C (fi) | Foerfarande foer framstaellning av nya, ur klebsiella pneumoniae extraherade glykoproteiner. | |
| JPH10298105A (ja) | 腸管出血性大腸菌による感染症の予防剤および治療剤 | |
| RU2043772C1 (ru) | Способ получения сыворотки, антиадгезивной и антитоксической против эшерихиоза сельскохозяйственных животных | |
| JPH0669962B2 (ja) | 経口免疫グロブリン | |
| Steabben | A study on bacteriological lines of the antigens derived from Bact. dysenteriae Shiga and of their antisera in protective tests against the living organisms | |
| Powers et al. | Complement-independent binding of microorganisms to primate erythrocytes in vitro by cross-linked monoclonal antibodies via complement receptor 1 | |
| JPS6160051B2 (enrdf_load_stackoverflow) | ||
| JP4014330B2 (ja) | ウイルス感染防御剤 | |
| Stollerman et al. | Natural resistance of germ-free mice and colostrum-deprived piglets to Group A streptococci |